Divalproex Sodium Tablet, Delayed Release
Product Images NDC 50090-4861

7 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-4861). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 01)

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 01)
Chemical structure of Divalproex Sodium, showing the sodium salt form of the valproic acid dimer with its chemical bonds and molecular groups, represented within parentheses and subscript notation for polymerization (n).*
FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 02)

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 02)
A bar chart comparing two studies measuring percentages labeled as PBO and DVPX in Study 1 (years) and Study 2 (months). Study 1 shows 26% for PBO and 60% for DVPX. Study 2 shows 29% for PBO and 58% for DVPX. The y-axis represents percentage values from 0% to 70%.*
FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 03)

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 03)
A line graph comparing the percentage reduction in Clinical Psychiatric Scale (CPS) rate between Divalproex Sodium and placebo across different percentages of patients. The vertical axis shows % reduction in CPS rate from -100% (worsening) to 100% (improvement), while the horizontal axis represents % of patients from 100% to 0%. Solid and dashed lines represent Divalproex Sodium and placebo, respectively.*
FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 04)

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 04)
A cumulative distribution plot depicting the percentage reduction in CPS rate for patients on high and low doses of Divalproex Sodium delayed-release tablets. The chart shows improvement or worsening effects on the vertical axis, with patient percentages decreasing from left to right on the horizontal axis. Two lines represent high dose (solid) and low dose (dashed) response rates.*
FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 05)

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 05)
A bar chart comparing two studies showing measurements for Placebo and Divalproex Sodium groups. The Y-axis represents numerical values, with Placebo bars higher than Divalproex Sodium in both studies, indicating varying levels measured across the two groups.*
FDA Label Image

Image (8e888ed9 2d55 4e95 Ba7b 8b437481c947 1830 2)

FDA Label Image

Label Image (Lbl500904861)

Label Image (Lbl500904861)
Divalproex Sodium 125 mg delayed-release tablets packaging label from A-S Medication Solutions. The label includes product NDC 50090-4861, specifies the oral route, storage instructions at 68 to 77 degrees F, and indicates a count of 30 tablets per package. The label also provides drug equivalency information and a QR code for dosage package insert details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.